With the gradual deepening of China's aging society and the continuous improvement of the service capabilities of comprehensive tertiary hospitals, the importance of primary healthcare in the "graded diagnosis and treatment" process is becoming increasingly prominent.
Image source: National Health Commission official website
In June 2022, the Notice on Deepening the "Quality Service Grassroots Campaign" and Community Hospital Construction (National Health Office Grassroots Letter [2022] No. 183) was issued, which clearly stated that during the 14th Five Year Plan period, efforts will be made to ensure that township health centers and community health service centers generally meet the basic service capacity standards, and some meet the recommended standards.
According to observations, several community health centers in Beijing are actively transforming and continuously improving their service levels. As a representative of this, the "Xiangheyuan Community Health Service Center" in Chaoyang District, Beijing is located at Building 15, Liufangnanli, Xiangheyuan Street. It was established in 2006 and has a building area of 1996 square meters. The center has three standard community health service stations, located in Xibahe Zhongli Community, Xibahe Dongli Community, and Xibahe Nanli Community.
At present, Xiangheyuan Community Health Service Center has more than ten clinical departments, including general practice, traditional Chinese medicine, dentistry, rehabilitation, health care, pediatrics, gynecology, functional imaging, radiology, laboratory medicine, psychosomatic medicine, and home bed visit; Undertaking the basic medical and public health management work for the 49000 permanent residents in Xiangheyuan area.
In order to further improve the coverage of health management for young/elderly populations, Xiangheyuan Community Health Service Center recently completed the installation and commissioning of Suzhou Guoke Junhao's MDA-20 Pro fully automatic chemiluminescence immunoassay analyzer, which is used to carry out growth and development related testing projects such as vitamin D, folate, ferritin, etc.
As a leading enterprise in the field of microfluidic technology platforms, Suzhou Guoke Junhao is committed to providing faster, more accurate, intelligent, and worry free in vitro diagnostic services. The MDA-20 Pro model can achieve whole blood sampling through internal centrifugation and secondary quantification of extremely small amounts of samples, simplifying the operation process and shortening the overall detection time; Supporting peripheral blood transfusion has further improved the sampling compliance of young children; The advantages of stacking no liquid pipelines, no maintenance costs, and no need for waste liquid treatment; The methodology of chemiluminescence is also superior to traditional immunofluorescence/colloidal gold techniques in terms of detection sensitivity.
I believe that MDA-20 Pro will definitely become a powerful assistant for clinical testing.